Brief: Assembly Biosciences Initiates Phase 1B Clinical Trial Evaluating Next Generation Core Inhibitor Abi-H3733
06/06/2022 13:39
June 6 (Reuters) - Assembly Biosciences Inc ASMB.O :
* ASSEMBLY BIOSCIENCES INITIATES PHASE 1B CLINICAL TRIAL
EVALUATING NEXT GENERATION CORE INHIBITOR ABI-H3733 FOR THE
TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION
Source text for Eikon: ID:nGNX7zY5d8
Further company coverage: ASMB.O
((reuters.briefs@thomsonreuters.com;))